$-15.59
(Market cap
$5 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
0.2
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$67 Mln
-
ROE
0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
3,741,140
8 Years Aggregate
CFO
$-482.24 Mln
EBITDA
$-554.96 Mln
Net Profit
$-471.91 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AVROBIO (AVRO)
| -91.1 | -91.3 | -90.4 | -89.5 | -76.5 | -61.7 | -- |
|
BSE Sensex*
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
AVROBIO (AVRO)
| 90.8 | -81.6 | -72.4 | -30.8 | 20.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AVROBIO (AVRO)
|
1.5 | 5.2 | 3.6 | 30.3 | -1,439.5 | 31.6 | 0.2 | 0.6 |
| 0.0 | 0.0 | -- | -- | -- | -- | -- | 0.0 | |
| 0.4 | 1.4 | 0.0 | -14.3 | -- | -121.4 | -- | 0.2 |
Shareholding Pattern
View DetailsAbout AVROBIO (AVRO)
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then... modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read more
-
President, Interim CEO, CFO & Treasurer
Mr. Erik John Ostrowski M.B.A.
-
President, Interim CEO, CFO & Treasurer
Mr. Erik John Ostrowski M.B.A.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AVROBIO (AVRO)
What is the current share price of AVROBIO Inc (AVRO) Today?
The share price of AVROBIO Inc (AVRO) is $1.45 (NASDAQ) as of 20-Jun-2024 17:53 EDT. AVROBIO Inc (AVRO) has given a return of -76.52% in the last 3 years.
What is the current PB & PE ratio of AVROBIO Inc (AVRO)?
The P/E ratio of AVROBIO Inc (AVRO) is 0.17 times as on 20-Jun-2024.
The P/B ratio of AVROBIO Inc (AVRO) is 0.60 times as on 20-Jun-2024, a 87 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of AVROBIO Inc (AVRO)?
The 52-week high and low of AVROBIO Inc (AVRO) are Rs -- and Rs -- as of 07-Jun-2026.
What is the market cap of AVROBIO Inc (AVRO)?
AVROBIO Inc (AVRO) has a market capitalisation of $ 5 Mln as on 20-Jun-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in AVROBIO Inc (AVRO)?
Before investing in AVROBIO Inc (AVRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.